/
Neurology
Secondary Progressive Multiple Sclerosis
13
Pipeline Programs↗
11
Active Trials↗
11
Companies Involved↗
Secondary Progressive Multiple Sclerosis is an emerging landscape with 13 programs across 11 companies. The most active players are Sanofi, Novartis, Kyverna Therapeutics. 5 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical4
Phase 1
No programs
Phase 24
Phase 35
Approved
No programs
Analysis
Modality Breakdown
12programs
Small molecule758%
Monoclonal antibody433%
Cell therapy18%
Modality classified for 100% of 13 pipeline programs.
Analysis
Trial Status
37
clinical trials
Completed16 · 43%
Recruiting7 · 19%
Terminated6 · 16%
Active, not recruiting3 · 8%
Withdrawn2 · 5%
No longer available1 · 3%
Other2 · 5%
Clinical Trials
Trial Activity
37 trials
The Effect of Rituximab on Cognitive and Hand Functions in Secondary Progressive Multiple Sclerosis
Recruiting·—·Phase 2·NCT06599307·46 enrolled
Page 1 of 3
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)